A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)

This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating Endometrial Cancer (EC) compared to standard of care. The study also assesses whether Mo-Rez is safe and tolerated well by participants in comparison to standard of care and will help provide a better understanding of the main side effects of the drugs.

Trial Details

NCT ID
NCT07286331
Phase
PHASE3
Sponsor
GlaxoSmithKline
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • Mocertatug rezetecan
  • Paclitaxel
  • Doxorubicin
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Omaha, Nebraska, United States|41.25626,-95.94043
  • Sugar Land, Texas, United States|29.61968,-95.63495
  • Charlottesville, Virginia, United States|38.02931,-78.47668
  • Florida, Buenos Aires, Argentina|-34.53258,-58.49078

Key Eligibility Criteria

  • Participants are eligible to be included in the study only if all of the following criteria apply:
  • Is at least 18 years of age and the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the Informed…
  • Has histologically confirmed endometrial carcinoma including but not limited to endometroid, serous, clear cell, and endometrial carcinosarcoma. Mi…
  • Has undergone at least 1 and no more than 2 lines of prior systemic treatment for EC. Up to 3 lines of prior systemic treatment are acceptable if o…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →